The Research Pharmacy Core has a well-developed system for the monitoring, coordination, and support of research pharmacy activities at DF/HCC member institutions. This facility has been approved and funded by the CCSG since 2004, when it received excellent merit. The Core assures consistency in policies across the sites (including policies relating to the receipt, storage, formulation, and dispensation of investigational agents), facilitates best practices, and monitors performance through a quality assurance program coordinated through the inter-institutional Research Pharmacy Core Committee. The Research Pharmacy participates in the DF/HCC Scientific Review and Monitoring Committees (PRMS) and Data and Safety Monitoring (DSM) program, as well as other relevant Cancer Center clinical trials oversight, monitoring, and policy initiatives. Director: Sylvia Bartel, RPh, MHP Category: 4.03 (Research Pharmacy) Management: Cancer Center Managed
The Research Pharmacy enables DF/HCC clinical investigators to conduct cancer-relevant research with a minimum of organizational encumbrances and differences in practice. The Research Pharmacy serves as a central point for the unification and integration of research-related pharmacy activities, fostering a coordinated clinical trials program within a multi-institution Comprehensive Cancer Center.
| Oxnard, Geoffrey R; Hu, Yuebi; Mileham, Kathryn F et al. (2018) Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncol 4:1527-1534 |
| Patil, Prasad; Parmigiani, Giovanni (2018) Training replicable predictors in multiple studies. Proc Natl Acad Sci U S A 115:2578-2583 |
| Agoston, Agoston T; Pham, Thai H; Odze, Robert D et al. (2018) Columnar-Lined Esophagus Develops via Wound Repair in a Surgical Model of Reflux Esophagitis. Cell Mol Gastroenterol Hepatol 6:389-404 |
| Barber, Lauren; Gerke, Travis; Markt, Sarah C et al. (2018) Family History of Breast or Prostate Cancer and Prostate Cancer Risk. Clin Cancer Res 24:5910-5917 |
| Kwee, Brian J; Budina, Erica; Najibi, Alexander J et al. (2018) CD4 T-cells regulate angiogenesis and myogenesis. Biomaterials 178:109-121 |
| Madsen, Thomas; Braun, Danielle; Peng, Gang et al. (2018) Efficient computation of the joint probability of multiple inherited risk alleles from pedigree data. Genet Epidemiol 42:528-538 |
| Chen, Jingjing; Guccini, Ilaria; Di Mitri, Diletta et al. (2018) Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. Nat Genet 50:219-228 |
| Li, Andrew G; Murphy, Elizabeth C; Culhane, Aedin C et al. (2018) BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1? activation. Proc Natl Acad Sci U S A 115:E9600-E9609 |
| McBrayer, Samuel K; Mayers, Jared R; DiNatale, Gabriel J et al. (2018) Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell 175:101-116.e25 |
| Stopsack, Konrad H; Gonzalez-Feliciano, Amparo G; Peisch, Samuel F et al. (2018) A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status. Cancer Epidemiol Biomarkers Prev 27:1231-1233 |
Showing the most recent 10 out of 411 publications
